Skip to content
Guiding immunotherapy based on the oxford classification activity score in IgA nephropathy
Back to full profile

BCL-2 inhibitor

Sonrotoclax

Beqalzi · SON

BCL-2 inhibitor · approved 2026 · 6 references

A second-generation BCL-2 inhibitor more potent than venetoclax — and its kidney risk is the same one that defines the class: tumor lysis syndrome, not tubular poisoning.

Signature injury
Crystal / Obstructive Nephropathy
Severity
Severe
Reversibility
Variable
Onset
Early and dose-timed. Tumor lysis clusters around the initial ramp-up doses and the first full target dose — the window of maximal, synchronous cytoreduction — typically developing within about 12–72 hours of an effective dose. Kidney injury therefore concentrates in the first days of treatment and at each dose escalation, with risk falling once the bulk of disease has been debulked and full dosing is tolerated. This front-loaded timing is the entire rationale for the stepwise ramp-up.

Signature kidney injury & incidence

Crystal / Obstructive Nephropathy.

No clean, drug-specific published incidence of sonrotoclax acute kidney injury exists as a discrete endpoint; the renal risk is inferred from the tumor-lysis physiology that defines potent BCL-2 inhibition. The precedent is venetoclax, where laboratory and clinical tumor lysis syndrome were frequent enough — including early fatal cases — that a mandatory ramp-up schedule, risk-stratified prophylaxis, and inpatient monitoring became standard of care (Tambaro & Wierda, Lancet Haematol 2020). Because sonrotoclax is more potent than venetoclax and induces apoptosis faster, its tumor-lysis potential is at least as high, which is precisely why its development and label built in a stepwise dose ramp-up from the outset. Reported drug-specific AKI rates should not be overstated until mature peer-reviewed trial safety data are published.

Source: No drug-specific AKI incidence yet; TLS risk inferred from the BCL-2 class (venetoclax paradigm — Tambaro & Wierda, Lancet Haematol 2020)

Reported injury signatures: Crystal / Obstructive Nephropathy, Electrolyte Disturbance, Prerenal / Hemodynamic AKI, Acute Tubular Necrosis.

Renal toxicity profile

  1. Crystal / Obstructive NephropathyPrimary
  2. Electrolyte DisturbanceSecondary
  3. Prerenal / Hemodynamic AKISecondary
  4. Acute Tubular NecrosisSecondary

Onset timing & rechallenge

Acute (~1–7 days) — Tumor lysis clusters around the ramp-up doses and the first full target dose, typically within ~12-72 hours of an effective dose; kidney injury is front-loaded to the first days of treatment and each escalation.

Mechanism of kidney injury

The kidney injury is a downstream consequence of on-target pharmacology, not intrinsic nephrotoxicity. By potently inhibiting BCL-2, sonrotoclax drives rapid, synchronous apoptosis of a large malignant B-cell mass; the dying cells spill intracellular potassium, phosphate, and purines. Purines are catabolized to uric acid, and uric acid plus calcium-phosphate then precipitate as intratubular crystals, producing obstructive and inflammatory crystal nephropathy — the classic mechanism of tumor-lysis acute kidney injury (Howard, Nat Rev Dis Primers 2024). Hyperphosphatemia with secondary hypocalcemia and hyperkalemia complete the metabolic storm; volume depletion and any concurrent nephrotoxin amplify tubular urate/phosphate concentration and precipitation. The lesson learned with venetoclax — that potency translates directly into tumor-lysis risk requiring graded exposure — applies with at least equal force to this more potent successor (Tambaro & Wierda, Lancet Haematol 2020). The parent drug itself is cleared largely by hepatic metabolism and biliary/fecal excretion rather than by the kidney (Cai, Cancer Chemother Pharmacol 2025), so renal impairment is not the route of elimination — the kidney is the victim of lysis, not the clearance organ.

Clinical presentation

AKI appears as part of a tumor-lysis picture rather than an isolated creatinine rise: within hours to a few days of an effective (often ramp-up) dose, uric acid, phosphate, potassium, and LDH climb while calcium falls, sometimes with cramps, tetany, arrhythmia, or seizure. Oliguria and a rising creatinine track the crystal load and any volume depletion. The urine sediment is typically bland or shows urate/phosphate crystals. In the absence of tumor lysis, sonrotoclax is not expected to produce a distinct tubular or glomerular lesion.

Management

Management targets the tumor-lysis syndrome, not the drug's clearance. Give aggressive IV hydration to restore renal perfusion and flush the tubules; treat hyperuricemia with rasburicase for significant or established elevations (allopurinol for lower-risk prophylaxis); manage hyperkalemia and hyperphosphatemia medically; and correct calcium only if symptomatic, since repleting calcium into a hyperphosphatemic milieu risks calcium-phosphate deposition. Provide standard supportive AKI care and avoid additional nephrotoxins. Escalate to renal replacement therapy for refractory hyperkalemia, severe symptomatic hyperphosphatemia/hypocalcemia, volume overload, or oliguric AKI unresponsive to medical measures. Interrupt sonrotoclax and re-ramp per protocol for clinical tumor lysis or significant AKI; the ramp-up schedule exists precisely so that dosing can be paused and resumed at a lower step rather than abandoned.

Risk factors

  • High tumor burden / bulky nodal disease or high circulating lymphocyte count (greater lysable mass)
  • High baseline LDH, uric acid, or phosphate (tumor-lysis-prone biochemistry)
  • The ramp-up doses and first full target dose (peak lysis window)
  • Pre-existing chronic kidney disease or volume depletion
  • Concurrent nephrotoxins or agents that impair uric-acid/phosphate handling
  • Rapid dose escalation or omission of tumor-lysis prophylaxis
  • Rapidly proliferative, chemosensitive disease

Prevention

  • Risk-stratify for tumor lysis before dosing (tumor bulk, LDH, uric acid, phosphate, renal function) and assign prophylaxis accordingly
  • Use the mandated stepwise dose ramp-up — never start at the full target dose — to limit the magnitude of each lysis wave
  • Vigorous IV hydration around the ramp-up and first full dose to maintain urine output and dilute tubular urate/phosphate
  • Allopurinol for standard tumor-lysis risk; rasburicase for high risk or established hyperuricemia (avoid rasburicase in G6PD deficiency)
  • Frequent tumor-lysis labs and inpatient/observed dosing during the high-risk window per protocol
  • Correct volume depletion and hold or minimize other nephrotoxins before escalation

Renal dose adjustment

No validated pharmacokinetic renal dose adjustment is established. Sonrotoclax is cleared predominantly by hepatic metabolism and biliary/fecal excretion rather than renal elimination (Cai, Cancer Chemother Pharmacol 2025), so creatinine clearance is not the primary determinant of exposure, and dedicated data in severe renal impairment or dialysis are limited. The clinically decisive dose lever is instead the mandated stepwise ramp-up, which controls tumor-lysis magnitude; dosing is interrupted, delayed, or re-escalated based on tumor-lysis and organ toxicity rather than on baseline GFR. Pre-existing CKD raises tumor-lysis-AKI risk and warrants intensified prophylaxis and monitoring even though it does not, by itself, mandate a lower milligram dose.

Dialyzability & ESKD dosing

Not meaningfully dialyzable as a therapeutic target: sonrotoclax is a small but highly protein-bound, lipophilic molecule cleared hepatically, so hemodialysis is not a route of drug removal and there is no role for dialysis to reverse an overdose of the parent compound. This is distinct from treating its complications — renal replacement therapy is a legitimate and sometimes necessary tool for the tumor-lysis metabolites (potassium, phosphate, uric acid) and for oliguric AKI; it clears the metabolic consequences, not the drug.

Differential diagnosis

The task is to recognize tumor lysis as the cause and exclude mimics. Tumor-lysis crystal nephropathy is favored by hyperuricemia, hyperphosphatemia, hyperkalemia, high LDH, and a falling calcium within 1–3 days of an effective or escalated dose, usually with a bland sediment and often a low fractional excretion of sodium early. Distinguish it from prerenal AKI due to poor intake or GI losses (which lacks the metabolic signature), from concomitant nephrotoxin or contrast exposure, and from pre-existing CKD. Unlike platinum agents or ifosfamide, sonrotoclax is not a primary proximal-tubular toxin — an isolated Fanconi picture or a slowly rising creatinine without electrolyte chaos points elsewhere.

Monitoring

  • Tumor-lysis panel (uric acid, phosphate, potassium, calcium, LDH, creatinine) at baseline and frequently during ramp-up and each dose escalation
  • Serial creatinine/eGFR to detect and grade AKI
  • Urine output and volume status during the high-risk window
  • ECG/telemetry when potassium or calcium derangements are significant
  • Adequacy of hydration and of allopurinol/rasburicase prophylaxis before each escalation

Key trials & series

  • Discovery and preclinical characterization (Guo, J Med Chem 2024) — identifies BGB-11417 (sonrotoclax) as a highly potent, selective BCL-2 inhibitor active against wild-type and G101V-mutant BCL-2 with selectivity over BCL-xL, the potency that underlies both its efficacy and its tumor-lysis risk.
  • Clinical development overview in hematologic malignancies (Bruzzese, Expert Opin Investig Drugs 2024) — summarizes the monotherapy and combination program across B-cell and myeloid malignancies that led toward approval.
  • BCL-2-inhibitor tumor-lysis experience (Tambaro & Wierda, Lancet Haematol 2020) — the venetoclax-anchored framework for tumor-lysis risk stratification, ramp-up dosing, prophylaxis, and treatment that governs how any potent BCL-2 inhibitor, including sonrotoclax, is administered safely.

Clinical pearls

  • The kidney is a bystander to apoptosis: sonrotoclax does not poison tubules — it lyses BCL-2-dependent tumor cells fast, and the released urate and phosphate crystallize in the tubule.
  • Potency cuts both ways: being more potent than venetoclax means at least as much tumor-lysis risk, which is why the stepwise ramp-up is mandatory, not optional.
  • Tumor lysis is front-loaded — risk peaks at the ramp-up and first full dose, so hydration, allopurinol/rasburicase, and frequent labs belong at initiation and at each escalation.
  • Treat the syndrome, not the drug: hydration and rasburicase are the levers for tumor-lysis AKI; the drug is hepatically cleared, so renal function does not drive its exposure.
  • Dialysis does not remove the parent drug, but renal replacement therapy is still the right tool for refractory tumor-lysis metabolites or oliguric AKI — clear the consequences, not the compound.
  • No drug-specific AKI rate is published yet — quote the venetoclax tumor-lysis experience as the honest reference, and let mature sonrotoclax trial data refine it.

Anticancer mechanism

Oral, highly potent and selective small-molecule inhibitor of the anti-apoptotic protein B-cell lymphoma-2 (BCL-2), engineered to bind both wild-type BCL-2 and the G101V mutant that mediates acquired resistance to venetoclax, with high selectivity over BCL-xL (sparing platelets). By occupying the BH3-binding groove of BCL-2, it displaces pro-apoptotic effectors (BIM, BAX, BAK) and triggers rapid mitochondrial apoptosis in BCL-2-dependent malignant B cells; its greater potency drives deeper, faster cytoreduction than venetoclax in preclinical and early clinical work.

Guidelines & consensus

  • ADQI (2026) — The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupProvides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.Nat Rev Nephrol · PMID 41361704
  • SIRM (2022) — SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.Radiol Med · PMID 35303246
  • KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerIdentifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.Kidney Int · PMID 33126977
  • KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationAddresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Kidney Int · PMID 33276867
  • ADDIKD (2025) — Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceProvides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.EClinicalMedicine · PMID 40290844
  • ADDIKD (2025) — Aligning kidney function assessment in patients with cancer to global practices in internal medicineThree consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.EClinicalMedicine · PMID 40290845
  • ADDIKD (2025) — A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEstablishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.EClinicalMedicine · PMID 40290846
  • KDIGO (2013) — Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.Crit Care · PMID 23394211
  • KDIGO (2021) — Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesProvides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.Kidney Int · PMID 34556300
  • KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisUpdates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.Kidney Int · PMID 38388147
  • KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisUpdates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.Kidney Int · PMID 38182299
  • KDIGO (2025) — Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.Kidney Int · PMID 40975525

References

6 peer-reviewed references. Citation metadata via PubMed / NLM.

  1. 1.Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.Guo Y, Xue H, Hu N, et al. · J Med Chem · 2024 · PMID 38695063
  2. 2.Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.Tambaro FP, Wierda WG. · Lancet Haematol · 2020 · PMID 32004486
  3. 3.Tumour lysis syndrome.Howard SC, Avagyan A, Workeneh B, et al. · Nat Rev Dis Primers · 2024 · PMID 39174582
  4. 4.Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies.Bruzzese A, Martino EA, Labanca C, et al. · Expert Opin Investig Drugs · 2024 · PMID 38264792
  5. 5.Biotransformation and disposition of [14C]-labeled sonrotoclax ([14C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome.Cai T, Su D, Tang Z, et al. · Cancer Chemother Pharmacol · 2025 · PMID 40833598
  6. 6.Sonrotoclax (BGB-11417) synergistically amplifies the radiotherapy-elicited anti-tumor immune response.Ma M, Zhang Z, Tian C, et al. · Cancer Lett · 2025 · PMID 40311913
Educational monograph from NephTox (nephtox.com). Not medical advice — verify against current guidelines before any clinical decision.